Recent news and corporate updates regarding Turn Therapeutics center around its public market performance following its Nasdaq direct listing debut, its ongoing financing agreements, and the clinical advancement of its flagship antimicrobial wound care and dermatological treatments. Investors closely monitor the company's quarterly financial disclosures, cash burn metrics, research collaborations, and regulatory progress as management works to expand the commercial application of its core technology platforms across global healthcare markets.